# Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma

> **NCT02083211** · PHASE3 · COMPLETED · sponsor: **National Institute of Cancerología** · enrollment: 168 (estimated)

## Conditions studied

- Cervical Cancer Recurrent or Persistent
- Palliative Treatment
- Monoclonal Antibody in Cervical Cancer Treatment

## Interventions

- **DRUG:** mAb Nimotuzumab
- **DEVICE:** Placebo

## Key facts

- **NCT ID:** NCT02083211
- **Lead sponsor:** National Institute of Cancerología
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2014-05
- **Final completion:** 2014-06
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2015-04-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02083211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02083211, "Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02083211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*